The company said it intends to cooperate with the request. The subpoena seeks documents from 1999 to the present generally related to Endo’s knowledge of the use of Lidoderm for off-label uses by physicians.
Pharmaceuticals companies are only allowed to promote drugs for the specific use for which it has been approved, although doctors are allowed to prescribe for any indication.
Endo has been and will continue to be firmly committed to promoting Lidoderm and all of Endo’s marketed products responsibly and appropriately within their currently approved indications, said Peter Lankau, president and CEO.
Lidoderm is a topical analgesic patch approved by the FDA in 1999 to treat the pain associated with post-herpetic neuralgia, a chronic condition resulting from nerve damage caused by shingles.